Parent-completed scales for measuring seizure severity and severity of side-effects of antiepileptic drugs in childhood epilepsy: development and psychometric analysis. by Arts, W.F.M. (Willem Frans) et al.
ELSEVIER Epilepsy Research 24 (1996) 173 - 181 
EPILEPSY 
RESEARCH 
Parent-completed scales for measuring seizure severity and 
severity of side-effects of antiepileptic drugs in childhood 
epilepsy: development and psychometric analysis 
Hans A. Carpay a,*, Wil lem F.M. Arts a Jan Vermeulen b, Hans Stroink c 
Oebo F. Brouwer d, A.C. Boudewyn Peters e, Cees A. van Donselaar f, 
Albert P. Aldenkamp b 
a Department ofChild Neurology, Westeinde Hospital and Juliana Children's Hospital, Den Haag, The Netherlands 
b Department ofPsychology, 'Meer en Bosch' Epilepsycentre, Heemstede, The Netherlands 
c Department ofChild Neurology, Sophia Children's Hospital / University Hospital Rotterdam, The Netherlands 
a Department ofChild Neurology, University Hospital Leiden, The Netherlands 
e Department of Child Neurology, University Hospital and Wilhelmina Children's Hospital Utrecht, The Netherlands 
f St. Clara Hospital Rotterdam, The Netherlands 
Received 11 October 1995; revised 2 February 1996; accepted 2 February 1996 
Abstract 
We have developed two outcome measures for childhood epilepsy: a seizure severity (SS) scale and a side-effects (SE) 
scale. Both scales have been designed for completion by parents. The scales were tested in two pilot phases and the results 
of this stepwise analy~,;is are described here. The final scales' psychometric properties were assessed in a group of 80 
children with active epilepsy, representative of the population at whom the scales were aimed: children with chronic 
epilepsy, aged 4-16 years, including all seizure types and epilepsies, as well as children with neurological comorbidity. The 
SS scale and SE scale showed good internal consistency and test-retest stability. Although there was a significant positive 
correlation between the SS scale and the SE scale, this was low, indicating that the scales measure a different clinical trait. 
The SE scale consisted of two subscales: a Toxic subscale, measuring the severity of dose-related side-effects, and a Chronic 
subscale, measuring the severity of long-tema behavioural nd cognitive side-effects. These subscales for side-effects showed 
a high correlation and can be used as a joint scale. These scales have the potential to improve outcome assessment in 
childhood epilepsy and they can be used to assess important aspects of quality of life in this population. 
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1. Introduction 
* Corresponding author Present address: Department of Clini- 
cal Neurophysiology, Westeinde Hospital, PO Box 432, 2501 CK 
Den Haag, The Netherlands. Tel.: +31 (70) 330 2000; fax: +31 
(70) 380 9459. 
During the past decade, several tools have been 
developed to improve the assessment of  treatment 
outcome in epilepsy [19]. These efforts have focused 
on epilepsy in adults. The high prevalence of  epilepsy 
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in children [13] and the fact that about 30% does not 
achieve total seizure control [3,12], suggest hat the 
development of similar measures of outcome for a 
childhood epilepsy population is indicated. Such 
measures can prove useful in research and clinical 
practice. 
The purpose of treating epilepsy is to improve the 
child's life. It is important o assess the effects of 
treatment on an individual basis. In the words of 
Freeman: 'We need to treat seizures when, for that 
individual, the risk of having seizures and the conse- 
quences of having more seizures are worse than the 
risks and consequences of the treatment i self' [11]. 
For clinicians concerned with epilepsy, the most 
important variables are frequency and severity of 
seizures, and prevalence and severity of side-effects 
of antiepileptic drugs (AEDs). How can a clinician 
determine whether an acceptable balance is achieved 
between seizure suppression and toxicity? In child- 
hood epilepsy, a reliable and valid inventory of the 
child' s health-related quality of life (QoL) [20], would 
probably provide useful answers [8,9]. 
QoL is generally seen as a multidimensional con- 
cept. In most studies addressing QoL in epilepsy, 
physical symptoms are neglected compared to psy- 
chosocial issues [14]. Measures of seizure severity 
and severity of side-effects are important aspects of 
the physical domain of QoL in epilepsy [1]. The 
methodological difficulties of self-report QoL assess- 
ments in a population of children with epilepsy 
[9,19] suggest that the use of parent-report instead of 
self-report scales is justified. The majority of chil- 
dren with chronic epilepsy lacks the skills required 
for reliable self-report, because they are mentally 
retarded [16] or simply too young. 
We describe two newly developed scales for par- 
ents of children with epilepsy: the The Hague seizure 
severity (SS) scale and the The Hague side-effects 
(SE) scale. These scales were designed to measure 
the parents' perception of these two basic aspects of 
severity of epilepsy in children. 
2. Methods 
2.1. Subjects 
Children were recruited from the outpatient popu- 
lations of the departments of child neurology of two 
hospitals in The Hague (one children's hospital and 
one general hospital) and the University Hospitals of 
Rotterdam, Leiden and Utrecht, four cities in the 
most densely populated area of the Netherlands. 
Parents were asked to participate by their child's 
own doctor and, after giving informed consent, they 
were asked to complete a mailed questionnaire, in- 
cluding both scales, at home. All questions referred 
to the child's condition during the previous 3 months. 
All parents completed the SS scale. The SE scale 
was completed only by parents of children who were 
treated with AEDs. 
The treating physicians - experienced child neu- 
rologists - classified the seizures and epilepsies ac- 
cording to the current ILAE Classifications [6,7]. 
2.1.1. Inclusion criteria 
Children aged 4-16 years, with a diagnosis of 
epilepsy and having experienced at least one seizure 
in the past 3 months were included, regardless of 
seizure type or syndrome diagnosis. The physicians 
were asked to select parents with sufficient Dutch- 
reading skills to complete a questionnaire, thus, ex- 
cluding most immigrant parents. 
2.2. Content 
We developed two scales to measure the parents' 
perception of the severity of seizures (SS scale) and 
of side-effects of AEDs (SE scale) in children with 
epilepsy. The 19-item pilot SS scale was a modified 
version of the Liverpool SS scale - a valid and 
reliable self-report scale for adults [2] - to which 
new items were added as suggested by the child 
neurologists who participated in the study. The 
definitive 13-item SS scale is presented in Appendix 
A. Questions 2, 3 and 7-13 have been translated 
from the Liverpool SS scale and subsequently modi- 
fied to allow completion by the parents. The Liver- 
pool scale includes some items with precise rather 
than subjective responses. We felt it was more con- 
sistent o include only items with subjective answer 
categories. 
The pilot SE scale was based on items suggested 
by the child neurologists. It also included an open 
question inviting the parents to suggest alternative or 
additional items which they considered important 
within the scope of the scale. 
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Ten sets of paren~Ls of children with uncontrolled 
epilepsy were asked to comment on the items and 
content of the pilot scales. Some questions were 
subsequently added or rephrased. To some items in 
the SS scale and all items in the SE scale, a response 
category 'unknown' was added, to allow completion 
in case of a permanent impairment (like mental 
retardation or cerebral palsy). When a child is always 
incontinent or unable to express certain complaints, 
it seems impossible for the parents to answer a 
question about such problems occurring during or 
after a seizure, or because of AED treatment. The 
most severe score possible on both scales for chil- 
dren with (severe) permanent impairments was con- 
sequently lower than for children without those im- 
pairments. 
Next, the scales were tested in two phases: (1) a 
pilot study in 25 pat~Lents, after which a preliminary 
psychometric evaluation was done; and (2) a subse- 
quent study in a larger population of 80 children and 
their parents, followed by a more extensive data 
analysis. We have chosen not to construct hese 
scales on the basis of factor analysis, but first of all 
to construct he most homogeneous scales possible 
as suggested by Nunally [17]. 
2.3. Psychometric and statistical analyses (SS and 
SE scales) 
2.3.1. Item analysis 
Two steps of item analysis were performed. (1) 
Corrected item-total correlations (CITCs) - the cor- 
relation between the :item and the rest of the scale - 
were calculated and items with a CITC < 0.20 were 
deleted. (2) Frequency distributions of answers were 
computed and items where one alternative was cho- 
sen in > 95% of cases were left out. 
2.3.2. Reliability analysis 
Crohnbach's alpha was computed as a measure of 
internal consistency of the final scales. A scale has 
sufficient internal consistency for research purposes, 
when alpha is at least 0.8 [23]. 
Test-retest reliability: of 22 consecutive parents 
who were asked to complete a second questionnaire 
14 days after the first, 18 parents responded. Pear- 
son's R was used as a measure of test-retest abil- 
ity. 
2.3.3. Distribution of the scores 
Items consisted of 4 or 5 point adjectival ques- 
tions. A simple scoring system was adopted with 
ratings ranging from 1 (most favourable) to 4 or 5 
(most unfavourable) points for each item. 
Scale mean scores, S.D. values and frequency 
distributions of scores were established as these mea- 
sures indicate the scales' potential to measure change. 
2.3.4. Correlations between scales and correlations 
with seizure frequency 
Spearman's rank correlation coefficient (R s) was 
used as a measure of the relationships between the 
scales and of each scale with seizure frequency. We 
used an estimation of seizure frequency in the pre- 
ceding 3 months by the parents. 
3. Results 
In the final study, 81 children and their parents 
were included. The parents of one child did not 
return the questionnaire. The analysis of the SS scale 
was, thus, based on 80 completed questionnaires. 
The parents of 75 children completed the SE scale as 
5 children were not treated with AEDs. The overall 
availability of data was excellent. None of the par- 
ents had any serious problems completing the scales. 
Demographic and clinical characteristics of the 
children included in the study are shown in Table 1. 
The majority of the children can be considered to be 
patients with intractable pilepsy. In 75% of the 
children, seizures were not under control after at 
least 1 year of therapy. Many children had symp- 
tomatic epilepsies and seizure types which are diffi- 
cult to control. Mild to severe mental retardation was 
present in 37 (46%) children. The distribution of the 
number of AEDs/child reflected current clinical 
practice as monotherapy dominated and some chil- 
dren were not treated with an AED despite recurrent 
seizures. However, as one might expect in this sam- 
ple, 40% of the children were treated with polyther- 
apy. 
3.1. SS scale 
3.1.1. Initial analysis of the pilot study 
One item concerning active seizure control by the 
child was left out. All 25 parents answered nega- 
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Table 1 
Demographic and clinical variables of the sample 
Number of children 
Mean age 
Sex 
Mean duration of epilepsy 
Epilepsy classification 
Seizure classification * 
Number of AEDs/patient 
80 
9.6 years (3.4) 
34 (43%) girls 
4.7 years (4.0) 
Localization-related 
- Idiopathic with age-related onset: 
12 (15%) 
- Symptomatic: 31 (39%) 
Generalized 
- Idiopathic with age-related onset: 
11 (14%) 
- Generalized idiopathic or 
symptomatic: 18 (23 %) 
Unclassified: 8 (10%) 
Simple partial: 18 
Complex partial: 24 
Secondary generalized: 15 
Absences: 14 
Myoclonic: 3 
Clonic: 1 
Tonic: 3 
Tonic-clonic: 9 
Atonic: 7 
No AED: 5 (6%) 
1 AED: 43 (54%) 
2 AEDs: 21 (26%) 
3 AEDs: 10 (13%) 
4 AEDs: 1 (1%) 
SD values of mean values are given between parentheses. 
* Seizure classification relates to seizures in the preceding 3 
months; 13 children had > 1 seizure type. 
tively. No other changes were found necessary after 
the analysis of the pilot results. 
Table 2 
Results of reliability analysis of the scales for SS, SE and 
subscales for toxic side-effects and chronic side-effects 
Scale Alpha Retest 
SS (13 items) 0.85 0.93 
SE (20 items) 0.88 0.91 
Subscales 
Toxic (14 items) 0.87 
Chronic (6 items) 0.81 
Alpha: Crohnbach's alpha (internal consistency). Retest: Pearson's 
R between first test score and retest score after 14 days. 
CITC values are listed in Appendix A. CITC values 
ranged from 0.22 to 0.70. The highest CITC, indicat- 
ing the item most representative of what the scale 
measures, was found for Q3 (How severe have the 
seizures been overall?). 
Table 2 presents the results of reliability analysis, 
which indicate good internal consistency (Crohn- 
bach's alpha 0.85) and a high test-retest correlation 
of 0.93. The distribution of the SS scale scores is 
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3.1.2. Final SS scale 
After the item analysis, we further reduced the 
number of items in the SS scale. Items deleted 
because of a low CITC related to the following 
symptoms. Interruption of activities by the seizure, 
disability to speak during the seizure and seizure-re- 
lated faecal incontinence. For several items relating 
to the same symptoms, we made a choice based on 
the best CITC. The final SS scale comprised 13 
items (Appendix A. 
The items represent the following areas of con- 
tent. Consciousness (4 questions), motor symptoms 
(2), incontinence (1), injuries/pain (3) and overall 
SS (3). Ictal symptoms are addressed in 9 and pre- 
dominantly postictal symptoms in 4 questions. The 
number of patients 
30 
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Fig. 1. Frequency distribution of scores. (A) The SS scale: clus- 
tered scores in 80 children. Mean score 30.5 (8.0). Least severe 
score possible = 13. Most severe score possible = 54. (B) The SS 
scale: clustered scores in 75 children using antiepileptic drugs. 
Mean score 27.9 (8.5). Least severe score possible = 20. Most 
severe score possible = 80. SD values of mean values are given 
between parentheses. 
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shown in Fig. la. So:me scores were obtained on the 
lower extreme of the scale, which implied that for 
these children the scale could not measure any im- 
provement. No scores were produced in the upper 
extreme range of the scale. The mean is > 2 S.D. 
values higher than tile lowest possible score and 3 
S.D. values lower thorn the highest possible score. 
3.2. SE scale 
3.2.1. Initial analysis of the pilot study 
The pilot SE scale was revised completely be- 
cause of ambiguity of certain items and insufficient 
internal consistency. We frequently found an incon- 
sistency in the paren~:s' response to a question con- 
cerning the presence of side-effects (12/24 parents 
reported 'no side-effects') and the subsequent re- 
sponses on a list of items representing the most 
common side-effects (10 of these 12 parents re- 
sponded positively to at least 1 item). Many parents 
added items to the pilot list of side-effects. Some of 
these items were included in a new 29-item version 
of the SE scale. 
Table 3 
Correlations between scores on the scales for SS, toxic side-ef- 
fects and chronic side effects (Spearman's  rank correlation) 
SE scale Toxic Chronic 
subscale subscale 
SS scale 0.25 0.20 0.23 
P = 0.027 P = 0.080 P = 0.048 
Toxic subscale 0.58 
P < 0.001 
n = 75. 
SE scale are shown in Fig. lb. On the SE scale many 
children produced a score in the lowest possible 
range and the mean score was < 1 S.D. from the 
scale's lowest value. Very few children obtained 
scores in the high range of the SE scale. 
The definitive SE scale is presented in Appendix 
B, including a list of CITC values. The CITC values 
range from 0.24 to 0.77. The item with the highest 
CITC in the Toxic subscale was 'Fatigue' (0.77) and 
in the Chronic subscale 'Decreased concentration' 
(0.64). 
3.2.2. Final SE scale 
After testing the new 29-item version, three items 
were deleted: one with 100% negative response 
(concerning vomiting), two with a low CITC (con- 
cerning sleeplessness and increase of appetite/obes- 
ity). The final SE scale was divided into three sub- 
scales, based on a clinical classification of the side- 
effects. The subscales were called 'Toxic' (14 items 
relating to dose-dependent gastro-intestinal and neu- 
rotoxic side-effects), 'Idiosyncratic' (6 items relating 
to gum hyperplasia, rash, hirsutism, hair loss, 
acne/pimples, itching) and 'Chronic' (6 items relat- 
ing to cognitive and behavioural side-effects). We 
felt it was appropriate to analyse the internal consis- 
tency of these subscales first, before defining the 
final SE scale. 
Internal consistency analysis of the subscales (n 
= 75) resulted in the following alpha scores: Toxic 
0.87; Idiosyncratic 0.47; Chronic 0.81. Alpha of the 
Idiosyncratic subscale was below the limit of 0.8, 
this subscale was consequently not included in the 
subsequent analysis. 
Test-retest stability of the SE scale was good 
(Table 2). Mean scores and score distribution of the 
3.3. Correlations 
Correlations between the SE scale, Toxic and 
Chronic SE subscales and the SS scale are shown in 
Table 3. These indicate that the SS scale and the SE 
scale measured a different rait as we found a low 
correlation between them. The Toxic and Chronic 
subscales largely measured the same clinical trait. 
There was a significant correlation between 
seizure frequency and the score on the SS scale: R s 
was -0.33 (P= 0.004). This means that frequent 
seizures are less severe. The correlation between 
seizure frequency and the score on the SE scale was 
not significant: R s was 0.18 (P  = 0.12). 
4. Discussion 
4.1. SS scale 
The 13-item SS scale is easy to administer and 
reliable in terms of internal consistency and retest 
stability. The distribution of scores obtained in this 
sample suggest he scale has adequate potential to 
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measure both positive and negative change in seizure 
severity. Its validity cannot be demonstrated using an 
external gold standard. However, face and content 
validity were appropriately established. Furthermore, 
the question with the highest CITC clearly addresses 
SS, supporting the idea that the scale measures what 
it was intended to measure. The negative correlation 
between seizure frequency and the score on the SS 
scale is in accordance with clinical intuition and 
suggests that parents are able to separate seizure 
frequency and severity. Further evidence of construct 
validity must be obtained from subsequent clinical 
studies. 
It is well-recognized that assessment of SS adds 
to the overall reliability, sensitivity and clinical rele- 
vance of research on treatment outcome in uncon- 
trolled epilepsy [2,4,5,22,24]. In addition to a mea- 
sure of seizure frequency, the SS scale can provide a 
complete seizure-based outcome system for studies 
in uncontrolled childhood epilepsy. It is likely that 
for children with recurrent seizures it provides useful 
information pertaining to their QoL. 
4.2. SE scale 
The SE scale and its subscales have adequate 
internal consistency and retest stability. Mean scores 
were very close to the best possible scores. This 
indicates that prevalence and severity of side-effects 
in the majority of the study population were limited. 
This easily administered scale seems a useful and 
valid screening tool for identifying children with 
gastro-intestinal and neurotoxic side-effects. It is im- 
portant o emphasize that the SE scale was tested in 
an unselected sample of patients who have been 
treated for a long time. Tolerance to dose-dependent 
side-effects may have reduced the scores on side-ef- 
fects as addressed in the Toxic subscale [10,15]. 
Probably, if children had been selected shortly after 
starting new medication, higher scores for dose-de- 
pendent side-effects might have resulted. 
The Idiosyncratic subscale failed the standard of 
internal consistency. This means that the symptoms 
and signs grouped in this subscale do not represent a 
homogeneous construct. The summation of scores 
over a number of items is appropriate only if all 
items are measuring the same trait [23]. Although the 
validity of this subscale seems strong, we can not 
confidently conclude that a summation of scores on 
the items addressing idiosyncratic side-effects i ap- 
propriate. They may be useful as single items ad- 
dressing idiosyncratic side-effects. One might argue 
that the Idiosyncratic subscale's low internal consis- 
tency is even supportive of the validity of the indi- 
vidual items. 
The considerable correlation between the Toxic 
and Chronic subscales makes it appropriate to use 
one SE scale including the items of both subscales, 
instead of separate subscales. We found no signifi- 
cant correlation between seizure frequency and the 
score on the SE scale. This suggests that parents are 
able to separate seizures from side-effects. However, 
the complex relations between seizures and side-ef- 
fects clearly warrant further studies. 
A quantification of subjective adverse ffects is of 
importance in epilepsy treatment [19]. Using a scale 
listing the most frequent side-effects may be a partic- 
ularly informative approach. In our pilot study, the 
majority of parents, reporting 'no side-effects' to a 
global question, did report complaints on a subse- 
quently presented list of side-effects. As such, the SE 
scale may contribute to a better screening for the 
presence of side-effects as well as to the assessment 
of their severity. 
4.3. Implications for future research and applica- 
tions 
Health measurement scales are time-consuming 
instruments. Consequently, focusing on relevant di- 
mensions might increase their acceptability. It is 
probable that for children with uncontrolled seizures, 
SS and severity of side-effects of AEDs are relevant 
issues. 
For an assessment of SS and severity of side-ef- 
fects in children, population-specific s ales are indi- 
cated as scales developed for an adult population are 
not appropriate [19]. As self-report in young children 
is not a reliable alternative, it seems justified to 
apply parent-report instruments for QoL assessments 
in childhood disease [18]. This would also seem to 
be a sensible approach in retarded children or adoles- 
cents, when they are still being cared for by their 
parents. Some considerations favour the use of par- 
ents rather than physicians as the source of informa- 
tion about seizures and side-effects. (1) Seizures are 
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rarely witnessed by the physician. Any assessment of
their severity by the: physician will be based on a 
description by others and by general medical percep- 
tions. (2) The severity of most side-effects can not be 
assessed objectively. Cognitive and behavioural 
side-effects may be examined with standardized neu- 
ropsychological test,;, but these are not as easily 
administered as the SE scale, and not always appro- 
priate for this population. It should be noted that 
patient - or parent - perceived severity of disease 
does not necessarily parallel the physician's view 
[21]. We are conducting a study to compare the 
parents' scores on the SS and SE scales and the 
physicians' clinical global impression of SS and 
severity of side-effects. 
Sensitivity to clinJLcally relevant change is an im- 
portant quality of any clinimetric instrument devel- 
oped to assess treatment effects. We are investigating 
this issue in a 1-year follow-up study using the SS 
scale and SE scale. Further studies in a larger sample 
are conducted to provide more data on the clinical 
validity of both sca]es. An English version of the 
Dutch SS and SE scales has been completed and will 
be subjected to a simi:lar study to assess their reliabil- 
ity and validity in a comparable Western inner city 
population. 
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Appendix A. SS scale and CITC values in 80 
children 
Questions relate to your child's seizures in the 
past 3 months. 
Q1. How often do you notice a decrease of con- 
sciousness during a seizure in your child? (C ITC = 
0.33) 
a. always 
b. usually 
c. sometimes 
d. never 
Q2. How long does such a decrease of conscious- 
ness last? (From time of onset to time of normal 
consciousness) ( C ITC  = 0.59) 
a. very long 
b. long 
c. short 
d. very short 
Q3. How severe have the seizures been overall? 
(C ITC = 0.70) 
a. very severe 
b. severe 
c. mild 
d. very mild 
Q4. Are there any muscle jerks or cramps in the 
arms or legs during an attack? (C ITC = 0.48) 
a. always 
b. usually 
c. sometimes 
d. never 
Q5. How long do the jerks or cramps last during 
an attack? (C ITC = 0.54) 
a. very long 
b. long 
c. short 
d. very short 
e. does not apply, there are no jerks or cramps 
Q6. How noticeable are the seizure symptoms? 
(C ITC = 0.64) 
a. very noticeable, everyone will notice an attack 
b. fairly noticeable, most people will notice an 
attack 
c. not very noticeable, most people will not notice 
d. not at all noticeable, you have to be very alert 
to notice an attack 
Q7. During or after an attack, how often does 
your child seem confused? (C ITC = 0.49) 
a. always 
b. usually 
c. sometimes 
d. never 
Q8. During an attack, how often does your child 
wet him/herself? (C ITC = 0.41) 
a. always 
b. usually 
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c. sometimes 
d. never or unknown, my child is permanently 
incontinent 
Q9. During an attack, how often does your child 
bite his/her tongue? (C ITC 0.49) 
a. always 
b. usually 
c. sometimes 
d. never 
Q10. How often does your child become injured 
during an attack (other than biting the tongue)? 
(C ITC = 0.22) 
a. always 
b. usually 
c. sometimes 
d. never 
Q11. After the attack has finished, is your child 
sleepy? (including sleepiness caused by the use of 
rescue medication like diazepam) (C ITC = 0.67) 
a. always 
b. usually 
c. sometimes 
d. never 
Q12. After an attack, does your child complain of 
sickness, headache and/or  pain in the muscles? 
(C ITC = 0.43) 
a. always 
b. usually 
c. sometimes 
d. never or unknown, my child would not be able 
to complain about that 
Q13. After an attack, how long does it take, until 
your child can resume normal activity? (C ITC = 0.65) 
a. very long 
b. long 
c. short 
d. very short or direct after an attack 
(probable) cause, e.g. a handicap or a broken leg, 
this does not count as a side-effect. 
Have you noticed any of the following side-ef- 
fects of antiepileptic medication in your child during 
the past 3 months? 
a = yes, it is a very serious problem 
b = yes, it is a moderately serious problem 
c = yes, it is a mild problem 
d = no or not applicable or cannot be assessed 
because of impairment 
CITC 
1 drowsiness, sleepiness a .b .c .d .  0.62 
2 dizziness a .b .c .d .  0.48 
3 uncertainty when walking a .b .c .d .  0.66 
4 falling a .b .c .d .  0.56 
5 sickness a .b .c .d .  0.43 
6 difficulty with defecation a .b .c .d .  0.31 
7 diarrhoea a .b .c .d .  0.24 
8 shaking, trembling a .b .c .d .  0.45 
9 speech difficulties a .b .c .d .  0.41 
10 double or blurred vision a .b .c .d .  0.49 
11 headache a .b .c .d .  0.55 
12 fatigue a .b .c .d .  0.77 
13 loss of appetite a .b .c .d .  0.40 
14 depression a .b .c .d .  0.54 
15 hyperactivity a .b .c .d .  0.31 
16 temper tantrums, aggression a .b .c .d .  0.32 
17 slowness a .b .c .d .  0.61 
18 poorer school results a .b .c .d .  0.63 
19 decreased concentration a .b .c .d .  0.64 
20 behavioural disturbance a .b .c .d .  0.57 
CITCs relate to the full SE scale, which com- 
prises a subscale for toxic side-effects (items 1-14), 
and for chronic side-effects (items 15-20). 
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